Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

Key facts

Sponsor

DermBiont, Inc.

Principal Investigator

David Zepeda, MD

Zepeda Dermatologia

Intervention

DBI-102(drug)

Enrollment

75 target

Eligibility

18 years · All sexes

Timeline

2022 – 2023

Study locations (1)

• Zepeda Dermatologia, Santa Tecla, La Libertad Department, El Salvador

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hyperpigmentation of the skin

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07136766
  An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product
  Good Molecules, LLC
• ACTIVE NOT RECRUITINGNANCT07162623
  Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Oziva Bioactive Gluta Fizzy Effervescent Tablets on Subjects With Facial Dark Spots Such as Pimple Marks, Sunspots, Age Spots and Uneven Skin Tone
  NovoBliss Research Pvt Ltd
• RECRUITINGNANCT07067879
  The Effectiveness of a Novel Lip Product Containing Caulerpa Lentillifera Extract for Reducing Lip Hyperpigmentation
  Chulalongkorn University
• RECRUITINGNANCT06253468
  Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins
  Cosmetique Active International
• RECRUITINGNANCT06349447
  Pilot Study of LED for PIE and PIH
  Yanjun Dan
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07067515
  Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation
  Suez Canal University
• RECRUITINGNANCT05362929
  Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
  Albert Einstein College of Medicine

See all trials for Hyperpigmentation of the skin →